HOGA1 Gene Mutations of Primary Hyperoxaluria Type 3 in Tunisian Patients
- J Clin Lab Anal. 2017 May;31(3):e22053. doi: 10.1002/jcla.22053.
- 1. Biochemistry Department, LR12SP11, Sahloul University Hospital, Sousse, Tunisia.
- 2. Laboratory of Inborn Metabolic Diseases, Centre de Biologie Est, Hospices Civils de Lyon, Lyon, Bron Cedex, France.
- 3. Pediatric Department, Charles Nicolle University Hospital, Tunis, Tunisia.
- 4. Pediatric Department, LR12SP11, Sahloul University Hospital, Sousse, Tunisia.
Background: Primary hyperoxaluria type 3 (PH3) is due to mutations in the recently identified 4-hydroxy-2-oxoglutarate aldolase (HOGA1) gene. PH3 might be the least severe form with a milder phenotype with good preservation of kidney function in most patients. The aim of this study was to report three PH3 cases carrying mutations in HOGA1.
Materials and methods: Genetic analysis of HOGA1 was performed in patients with a high clinical suspicion of PH after Sequencing of AGXT and GRHPR genes, which was negative. Also, a complete AGXT/GRHPR MLPA was performed in these patients in order to detect large deletions/insertions.
Results and discussion: Two different HOGA1 gene mutations were identified: the p.Pro190Leu in a homozygous state and the p.Gly287Val in two patients in homozygous and heterozygous carriers. The median age at onset of clinical symptoms was 3.93 years. Most of the patients had a positive family history for recurrent urolithiasis. The p.Pro190Leu mutation was reported with impaired renal function at follow-up; however, the p.Gly287Val was presented with normal renal function. All patients were presented with urolithiasis, but only one had a nephrocalcinosis.
Conclusion: This study expanded the number of PH3 patients from 63 to 66 cases. The p.Pro190Leu and the p.Gly287Val mutations found in this study can provide a first-line investigation in Tunisian PH1 patients.